QuidelOrtho Q1 net loss $92M; revenue $620M; cuts full-year guidance

QuidelOrtho Corp

2026-Q1 EPS reported -$1.35 revenue$619,800,000

GAAP net loss $92M ($1.35 diluted loss per share); adjusted diluted EPS loss $0.04; revenue $620M.
Point of Care revenue $113M (-34% YoY) on weak respiratory season; Labs $353M (-5%); Immunohematology $138M (+8%).
Full-year 2026 guidance cut: revenue $2.70-2.75B (prev. $2.7-2.9B), adj. EBITDA $615-630M (prev. $630-670M), adj. EPS $1.80-2.00 (prev. $2.00-2.42).
Acquired LEX Diagnostics in April for ultra-fast point-of-care molecular diagnostics platform.
U.S. launch of High-Sensitivity Troponin and international rollout of VITROS 450 platform underway.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

QuidelOrtho Corp reported first quarter ended March 29, 2026 results: revenue $620 million. Guidance lowered.

Period: first quarter ended March 29, 2026
Revenue: $620 million
Guidance: lowered
Result: reported results

Exact text from the filing

Key First Quarter 2026 Results: (all comparisons are to the prior year period) • Total revenu e was $620 million , as reported ◦ Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025.

View on SEC.gov

Browse all earnings releases →

QuidelOrtho Corp filing history →

Source: SEC EDGAR

accession 0001906324-26-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.